19 results on '"Awasom, C."'
Search Results
2. Mycobacterium tuberculosis resistance in pulmonary TB patients in Cameroon: a phenotypic susceptibility assay
- Author
-
Achu P, Ayuk L, Robin M. Warren, Gerard Osterhout, Kim Dionne, Awasom C, Jubulis J, Noeske J, Nicole Parrish, and Carole McArthur
- Subjects
Pulmonary and Respiratory Medicine ,Tuberculosis ,Rifabutin ,biology ,business.industry ,Extensively drug-resistant tuberculosis ,Drug resistance ,medicine.disease ,biology.organism_classification ,Virology ,Mycobacterium tuberculosis ,Infectious Diseases ,medicine ,Ethionamide ,business ,Ethambutol ,Rifampicin ,medicine.drug - Abstract
OBJECTIVE To determine the resistance of Mycobacterium tuberculosis to first- and second-line agents in adult pulmonary tuberculosis (TB) patients in Cameroon using a novel phenotypic assay. SETTING Samples were collected from TB patients at Bamenda Hospital in Bamenda, Cameroon. DESIGN Samples were collected consecutively from adult pulmonary TB patients over a 2-month period. TREK Sensititre(TM) MYCOTB panels were used to perform phenotypic drug susceptibility testing (DST). Susceptibility/resistance was determined by comparing minimum inhibitory concentrations to standard critical concentrations established for first- and second-line anti-tuberculosis drugs. RESULTS Of 103 sputum samples processed, growth on Lowenstein-Jensen media was confirmed in 78 samples, 65 of which were suitable for DST. Thirty-nine strains (60%) were susceptible to all first- and second-line drugs. Five strains (8%) were categorized as multidrug-resistant TB. Two strains (3%) were classified as pre-extensively drug-resistant TB. Of those isolates susceptible to first-line drugs, 20% were resistant to at least one second-line drug. CONCLUSION Antimicrobial resistance may be higher than assumed in TB strains in Cameroon, especially with regard to second-line drugs. There remains a need for rapid, comprehensive DST. more...
- Published
- 2015
- Full Text
- View/download PDF
Catalog
3. Malaria over-diagnosis in Cameroon: diagnostic accuracy of Fluorescence and Staining Technologies (FAST) Malaria Stain and LED microscopy versus Giemsa and bright field microscopy validated by polymerase chain reaction
- Author
-
Parsel, S M, Gustafson, S A, Friedlander, E, Shnyra, A A, Adegbulu, A J, Liu, Y, Parrish, N M, Jamal, S A, Lofthus, E, Ayuk, L, Awasom, C, Henry, C J, and McArthur, C P
- Published
- 2017
4. Virological failure after 1 year of first-line ART is not associated with HIV minority drug resistance in rural Cameroon
- Author
-
Zoufaly, A., Jochum, J., Hammerl, R., Nassimi, N., Raymond, Y., Burchard, G. D., Schmiedel, S., Drexler, J. F., Campbell, N. K., Taka, N., Awasom, C., Metzner, K. J., van Lunzen, J., Feldt, T., Zoufaly, A., Jochum, J., Hammerl, R., Nassimi, N., Raymond, Y., Burchard, G. D., Schmiedel, S., Drexler, J. F., Campbell, N. K., Taka, N., Awasom, C., Metzner, K. J., van Lunzen, J., and Feldt, T. more...
- Abstract
Objectives The aim of this study was to describe clinical and virological outcomes in therapy-naive HIV-1-positive patients treated in a routine ART programme in rural Cameroon. Methods In a prospective cohort, 300 consecutive patients starting first-line ART were enrolled and followed for 12 months. Among 238 patients with available viral load data at Month 12, logistic regression was used to analyse risk factors for virological failure (≥1000 HIV RNA copies/mL) including clinical, immunological and virological parameters, as well as data on drug adherence. Population sequencing was performed to detect the presence of drug-resistance mutations in patients with virological failure at Month 12; minority drug-resistance mutations at baseline were analysed using next-generation sequencing in these patients and matched controls. Results At Month 12, 38/238 (16%) patients experienced virological failure (≥1000 HIV RNA copies/mL). Patients with virological failure were younger, had lower CD4 cell counts and were more often WHO stage 3 or 4 at baseline. Sixty-three percent of patients with virological failure developed at least one drug-resistance mutation. The M184V (n = 18) and K103N (n = 10) mutations were most common. At baseline, 6/30 patients (20%) experiencing virological failure and 6/35 (17%) matched controls had evidence of minority drug-resistance mutations using next-generation sequencing (P = 0.77). Lower CD4 count at baseline (OR per 100 cells/mm3 lower 1.41, 95% CI 1.02-1.96, P = 0.04) and poorer adherence (OR per 1% lower 1.05, 95% CI 1.02-1.08, P < 0.001) were associated with a higher risk of virological failure. Unavailability of ART at the treatment centre was the single most common cause for incomplete adherence. Conclusions Virological failure after 1 year of ART was not associated with minority drug resistance at baseline but with incomplete adherence. Strategies to assure adherence and uninterrupted drug supplies are pivotal factors for therapy succe more...
- Published
- 2017
5. Virological failure after 1 year of first-line ART is not associated with HIV minority drug resistance in rural Cameroon
- Author
-
Zoufaly, A, Jochum, J, Hammerl, R, Nassimi, N, Raymond, Y, Burchard, G D, Schmiedel, S, Drexler, J F, Campbell, N K, Taka, N, Awasom, C, Metzner, K J, van Lunzen, J, Feldt, T, Zoufaly, A, Jochum, J, Hammerl, R, Nassimi, N, Raymond, Y, Burchard, G D, Schmiedel, S, Drexler, J F, Campbell, N K, Taka, N, Awasom, C, Metzner, K J, van Lunzen, J, and Feldt, T more...
- Abstract
OBJECTIVES The aim of this study was to describe clinical and virological outcomes in therapy-naive HIV-1-positive patients treated in a routine ART programme in rural Cameroon. METHODS In a prospective cohort, 300 consecutive patients starting first-line ART were enrolled and followed for 12 months. Among 238 patients with available viral load data at Month 12, logistic regression was used to analyse risk factors for virological failure (≥1000 HIV RNA copies/mL) including clinical, immunological and virological parameters, as well as data on drug adherence. Population sequencing was performed to detect the presence of drug-resistance mutations in patients with virological failure at Month 12; minority drug-resistance mutations at baseline were analysed using next-generation sequencing in these patients and matched controls. RESULTS At Month 12, 38/238 (16%) patients experienced virological failure (≥1000 HIV RNA copies/mL). Patients with virological failure were younger, had lower CD4 cell counts and were more often WHO stage 3 or 4 at baseline. Sixty-three percent of patients with virological failure developed at least one drug-resistance mutation. The M184V (n = 18) and K103N (n = 10) mutations were most common. At baseline, 6/30 patients (20%) experiencing virological failure and 6/35 (17%) matched controls had evidence of minority drug-resistance mutations using next-generation sequencing (P = 0.77). Lower CD4 count at baseline (OR per 100 cells/mm(3) lower 1.41, 95% CI 1.02-1.96, P = 0.04) and poorer adherence (OR per 1% lower 1.05, 95% CI 1.02-1.08, P < 0.001) were associated with a higher risk of virological failure. Unavailability of ART at the treatment centre was the single most common cause for incomplete adherence. CONCLUSIONS Virological failure after 1 year of ART was not associated with minority drug resistance at baseline but with incomplete adherence. Strategies to assure adherence and uninterrupted drug supplies are pivotal factors for therapy suc more...
- Published
- 2015
6. Mycobacterium tuberculosis resistance in pulmonary TB patients in Cameroon: a phenotypic susceptibility assay
- Author
-
Jubulis, J., primary, Dionne, K., additional, Osterhout, G., additional, Ayuk, L., additional, Awasom, C., additional, Achu, P., additional, Noeske, J., additional, Warren, R., additional, McArthur, C., additional, and Parrish, N., additional more...
- Published
- 2015
- Full Text
- View/download PDF
7. Der Start anti-retroviraler Therapie bei Kindern im North West Regional Hospital in Bamenda, Kamerun
- Author
-
Sunjoh, F., Hammerl, R., Zoufaly, A., Feldt, T., Van Lunzen, J., and Awasom, C.
- Subjects
ddc: 610 ,virus diseases ,610 Medical sciences ,Medicine - Abstract
Introduction: In Cameroon, the number of HIV infected children on ARV increased over the last 5 years thanks to national treatment recommendations and financial support by the Global Fund. We analyzed a paediatric HIV treatment cohort in rural Cameroon to identify the challenges of successful implementation[for full text, please go to the a.m. URL], 10. Kongress für Infektionskrankheiten und Tropenmedizin (KIT 2010) more...
- Published
- 2010
- Full Text
- View/download PDF
8. Virological failure after 1 year of first-line ART is not associated with HIV minority drug resistance in rural Cameroon
- Author
-
Zoufaly, A., primary, Jochum, J., additional, Hammerl, R., additional, Nassimi, N., additional, Raymond, Y., additional, Burchard, G. D., additional, Schmiedel, S., additional, Drexler, J. F., additional, Campbell, N. K., additional, Taka, N., additional, Awasom, C., additional, Metzner, K. J., additional, van Lunzen, J., additional, and Feldt, T., additional more...
- Published
- 2014
- Full Text
- View/download PDF
9. Initiating paediatric anti-retroviral therapy in the North West regional Hospital in Bamenda, Cameroon
- Author
-
Sunjoh, F, Hammerl, R, Zoufaly, A, Feldt, T, van Lunzen, J, Awasom, C, Sunjoh, F, Hammerl, R, Zoufaly, A, Feldt, T, van Lunzen, J, and Awasom, C
- Published
- 2010
10. High HIV prevalence among children presenting for general consultation in rural Cameroon
- Author
-
Zoufaly, A, primary, Hammerl, R, additional, Sunjoh, F, additional, Jochum, J, additional, Nassimi, N, additional, Awasom, C, additional, Tayong, G, additional, Sauter, F, additional, Schmiedel, S, additional, van Lunzen, J, additional, Burchard, G, additional, and Feldt, T, additional more...
- Published
- 2014
- Full Text
- View/download PDF
11. High prevalence of hepatitis B and syphilis co-infections among HIV patients initiating antiretroviral therapy in the north-west region of Cameroon
- Author
-
Zoufaly, A, primary, Onyoh, E F, additional, Tih, P M, additional, Awasom, C N, additional, and Feldt, T, additional
- Published
- 2012
- Full Text
- View/download PDF
12. Virological failure after 1 year of first-line ART is not associated with HIV minority drug resistance in rural Cameroon
- Author
-
Zoufaly, A., Jochum, J., Hammerl, R., Nassimi, N., Raymond, Y., Burchard, G. D., Schmiedel, S., Drexler, J. F., Campbell, N. K., Taka, N., Awasom, C., Metzner, K. J., van Lunzen, J., Feldt, T., Zoufaly, A., Jochum, J., Hammerl, R., Nassimi, N., Raymond, Y., Burchard, G. D., Schmiedel, S., Drexler, J. F., Campbell, N. K., Taka, N., Awasom, C., Metzner, K. J., van Lunzen, J., and Feldt, T. more...
- Abstract
Objectives The aim of this study was to describe clinical and virological outcomes in therapy-naive HIV-1-positive patients treated in a routine ART programme in rural Cameroon. Methods In a prospective cohort, 300 consecutive patients starting first-line ART were enrolled and followed for 12 months. Among 238 patients with available viral load data at Month 12, logistic regression was used to analyse risk factors for virological failure (≥1000 HIV RNA copies/mL) including clinical, immunological and virological parameters, as well as data on drug adherence. Population sequencing was performed to detect the presence of drug-resistance mutations in patients with virological failure at Month 12; minority drug-resistance mutations at baseline were analysed using next-generation sequencing in these patients and matched controls. Results At Month 12, 38/238 (16%) patients experienced virological failure (≥1000 HIV RNA copies/mL). Patients with virological failure were younger, had lower CD4 cell counts and were more often WHO stage 3 or 4 at baseline. Sixty-three percent of patients with virological failure developed at least one drug-resistance mutation. The M184V (n = 18) and K103N (n = 10) mutations were most common. At baseline, 6/30 patients (20%) experiencing virological failure and 6/35 (17%) matched controls had evidence of minority drug-resistance mutations using next-generation sequencing (P = 0.77). Lower CD4 count at baseline (OR per 100 cells/mm3 lower 1.41, 95% CI 1.02-1.96, P = 0.04) and poorer adherence (OR per 1% lower 1.05, 95% CI 1.02-1.08, P < 0.001) were associated with a higher risk of virological failure. Unavailability of ART at the treatment centre was the single most common cause for incomplete adherence. Conclusions Virological failure after 1 year of ART was not associated with minority drug resistance at baseline but with incomplete adherence. Strategies to assure adherence and uninterrupted drug supplies are pivotal factors for therapy succe more...
13. Malaria over-diagnosis in Cameroon: diagnostic accuracy of Fluorescence and Staining Technologies (FAST) Malaria Stain and LED microscopy versus Giemsa and bright field microscopy validated by polymerase chain reaction.
- Author
-
Parsel SM, Gustafson SA, Friedlander E, Shnyra AA, Adegbulu AJ, Liu Y, Parrish NM, Jamal SA, Lofthus E, Ayuk L, Awasom C, Henry CJ, and McArthur CP
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Azure Stains, Cameroon, Child, Child, Preschool, Coloring Agents, Female, Humans, Infant, Malaria blood, Malaria parasitology, Male, Middle Aged, Prevalence, Young Adult, Malaria diagnosis, Microscopy methods, Polymerase Chain Reaction methods, Staining and Labeling methods
- Abstract
Background: Malaria is a major world health issue and its continued burden is due, in part, to difficulties in the diagnosis of the illness. The World Health Organization recommends confirmatory testing using microscopy-based techniques or rapid diagnostic tests (RDT) for all cases of suspected malaria. In regions where Plasmodium species are indigenous, there are multiple etiologies of fever leading to misdiagnoses, especially in populations where HIV is prevalent and children. To determine the frequency of malaria infection in febrile patients over an 8-month period at the Regional Hospital in Bamenda, Cameroon, we evaluated the clinical efficacy of the Flourescence and Staining Technology (FAST) Malaria stain and ParaLens Advance
TM microscopy system (FM) and compared it with conventional bright field microscopy and Giemsa stain (GS)., Methods: Peripheral blood samples from 522 patients with a clinical diagnosis of "suspected malaria" were evaluated using GS and FM methods. A nested PCR assay was the gold standard to compare the two methods. PCR positivity, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were determined., Results: Four hundred ninety nine samples were included in the final analysis. Of these, 30 were positive via PCR (6.01%) with a mean PPV of 19.62% and 27.99% for GS and FM, respectively. The mean NPV was 95.01% and 95.28% for GS and FM, respectively. Sensitivity was 26.67% in both groups and specificity was 92.78% and 96.21% for GS and FM, respectively. An increased level of diagnostic discrepancy was observed between technicians based upon skill level using GS, which was not seen with FM., Conclusions: The frequency of malarial infections confirmed via PCR among patients presenting with fever and other symptoms of malaria was dramatically lower than that anticipated based upon physicians' clinical suspicions. A correlation between technician skill and accuracy of malaria diagnosis using GS was observed that was less pronounced using FM. Additionally, FM increased the specificity and improved the PPV, suggesting this relatively low cost approach could be useful in resource-limited environments. Anecdotally, physicians were reluctant to not treat all patients symptomatically before results were known and in spite of a negative microscopic diagnosis, highlighting the need for further physician education to avoid this practice of overtreatment. A larger study in an area with a known high prevalence is being planned to compare the two microscopy methods against available RDTs. more...- Published
- 2017
- Full Text
- View/download PDF
14. Life With HIV: Insights from HIV-infected Women in Cameroon, Central Africa.
- Author
-
Alomepe J, Buseh AG, Awasom C, and Snethen JA
- Subjects
- Adult, Attitude of Health Personnel, Cameroon, Delivery of Health Care, Discrimination, Psychological, Female, HIV Infections diagnosis, HIV Infections drug therapy, Humans, Interviews as Topic, Middle Aged, Prejudice, Qualitative Research, Activities of Daily Living, HIV Infections psychology, Quality of Life psychology, Social Stigma, Social Support
- Abstract
Women in Cameroon are disproportionately burdened by HIV illness. Understanding the impact HIV has on women is essential for developing interventions to enhance their quality of life. Our aim was to explore and provide an in-depth understanding of the daily experiences of a sample of women living with HIV in Cameroon. Qualitative semi-structured in-depth interviews were conducted with women (N = 30) from the northwest region of Cameroon who self-reported being infected with HIV. Participants shared that they had multiple challenges in their daily experiences living with HIV. The themes that emerged included: (a) receiving an HIV diagnosis is traumatic, (b) living with HIV is a constant struggle, (c) limited resources and support cause problems, and (d) stigma and powerlessness exacerbate the impact of HIV. We provide insight into the daily experiences of HIV-infected women in Cameroon. Implications for improving health care and social services to women living with HIV in Cameroon are suggested., (Published by Elsevier Inc.) more...
- Published
- 2016
- Full Text
- View/download PDF
15. Effect of mild-to-moderate smoking on viral load, cytokines, oxidative stress, and cytochrome P450 enzymes in HIV-infected individuals.
- Author
-
Ande A, McArthur C, Ayuk L, Awasom C, Achu PN, Njinda A, Sinha N, Rao PS, Agudelo M, Nookala AR, Simon S, Kumar A, and Kumar S
- Subjects
- Adult, CD4 Lymphocyte Count, Female, HIV Infections enzymology, HIV Infections metabolism, Humans, Male, Middle Aged, Young Adult, Cytochrome P-450 Enzyme System metabolism, Cytokines metabolism, HIV Infections virology, Oxidative Stress, Smoking, Viral Load
- Abstract
Mild-to-moderate tobacco smoking is highly prevalent in HIV-infected individuals, and is known to exacerbate HIV pathogenesis. The objective of this study was to determine the specific effects of mild-to-moderate smoking on viral load, cytokine production, and oxidative stress and cytochrome P450 (CYP) pathways in HIV-infected individuals who have not yet received antiretroviral therapy (ART). Thirty-two human subjects were recruited and assigned to four different cohorts as follows: a) HIV negative non-smokers, b) HIV positive non-smokers, c) HIV negative mild-to-moderate smokers, and d) HIV positive mild-to-moderate smokers. Patients were recruited in Cameroon, Africa using strict selection criteria to exclude patients not yet eligible for ART and not receiving conventional or traditional medications. Those with active tuberculosis, hepatitis B or with a history of substance abuse were also excluded. Our results showed an increase in the viral load in the plasma of HIV positive patients who were mild-to-moderate smokers compared to individuals who did not smoke. Furthermore, although we did not observe significant changes in the levels of most pro-inflammatory cytokines, the cytokine IL-8 and MCP-1 showed a significant decrease in the plasma of HIV-infected patients and smokers compared with HIV negative non-smokers. Importantly, HIV-infected individuals and smokers showed a significant increase in oxidative stress compared with HIV negative non-smoker subjects in both plasma and monocytes. To examine the possible pathways involved in increased oxidative stress and viral load, we determined the mRNA levels of several antioxidant and cytochrome P450 enzymes in monocytes. The results showed that the levels of most antioxidants are unaltered, suggesting their inability to counter oxidative stress. While CYP2A6 was induced in smokers, CYP3A4 was induced in HIV and HIV positive smokers compared with HIV negative non-smokers. Overall, the findings suggest a possible association of oxidative stress and perhaps CYP pathway with smoking-mediated increased viral load in HIV positive individuals. more...
- Published
- 2015
- Full Text
- View/download PDF
16. Decentralised facility-based training as an alternative model for SLMTA implementation: The Cameroon experience.
- Author
-
Ndasi J, Dimite L, Mbome V, Awasom C, Ngale E, Akuro S, Leonard E, Bolu O, Asong T, Njukeng P, and Shang J
- Abstract
Background: The Strengthening Laboratory Management Toward Accreditation (SLMTA) programme is designed to build institutional capacity to help strengthen the tiered laboratory system. Most countries implement the SLMTA three-workshop series using a centralised model, whereby participants from several laboratories travel to one location to be trained together., Objectives: We assessed the effectiveness and cost of conducting SLMTA training in a decentralised manner as compared to centralised training., Methods: SLMTA was implemented in five pilot laboratories in Cameroon between October 2010 and October 2012 by means of a series of workshops, laboratory improvement projects and on-site mentorship. The first workshop was conducted in the traditional centralised approach. The second and third workshops were decentralised, delivered on-site at each of the five enrolled laboratories. Progress was monitored by repeated audits using the Stepwise Laboratory Quality Improvement Process Towards Accreditation (SLIPTA) checklist., Results: Audit scores for all laboratories improved steadily through the course of the programme. Median improvement was 11 percentage points after the first (centralised) training and an additional 24 percentage points after the second (decentralised) training. The estimated per-laboratory cost of the two training models was approximately the same at US$21 000. However, in the decentralised model approximately five times as many staff members were trained, although it also required five times the amount of trainer time., Conclusion: Decentralised SLMTA training was effective in improving laboratory quality and should be considered as an alternative to centralised training., Competing Interests: The authors declare that they have no financial or personal relationship(s) that may have inappropriately influenced them in writing this article. more...
- Published
- 2014
- Full Text
- View/download PDF
17. Determinants of HIV-1 drug resistance in treatment-naïve patients and its clinical implications in an antiretroviral treatment program in Cameroon.
- Author
-
Zoufaly A, Jochum J, Hammerl R, Nassimi N, Raymond Y, Burchard GD, Schmiedel S, Drexler JF, Kay CN, Taka N, Awasom C, Metzner K, Jan vL, and Feldt T
- Abstract
Introduction: Facing the rapid scale-up of antiretroviral treatment (ART) programs in resource-limited settings, monitoring of treatment outcome is essential in order to timely detect and tackle drawbacks [1]., Methods: In a prospective cohort study, 300 consecutive patients starting first-line ART were enrolled between 2009 and2010 in a large HIV treatment centre in rural Cameroon. Patients were followed up for 12 months. Virologic failure was defined as a VL >1000 cop/mL at month 12. Besides CD4 and viral load (VL) analysis, HIV-1 drug resistance testing was performed in patients with VL>1000 copies (c)/mL plasma. In those patients and controls, minority HIV-1 drug resistance mutations at baseline, and plasma drug levels were analyzed in order to identify the risk factors for virologic failure., Results: Most enrolled patients (71%) were female. At baseline median CD4 cell count was 162/µL (IQR 59-259), median log10 VL was 5.4 (IQR 5.0-5.8) c/mL, and one-third of patients had World Health Organisation (WHO) stage 3 or 4; 30 patients died during follow-up. Among all patients who completed follow-up 38/238 had virologic failure. These patients were younger, had lower CD4 cell counts and more often had WHO stage 3 or 4 at baseline compared to patients with VL<1000c/mL. Sixty-three percent of failing patients (24/38) had at least one mutation associated with high-level drug resistance. The M184V mutation was the most frequently detected nucleoside reverse transcriptase inhibitor (NRTI) mutation (n=18) followed by TAMs (n=5) and multi-NRTI resistance mutations (n=4). The most commonly observed non-nucleoside reverse-transcriptase inhibitor (NNRTI) resistance mutations were K103N (n=10), Y181C (n=7), and G190A (n=6). Drug resistance mutations at baseline were detected in 12/65 (18%) patients, in 6 patients with and 6 patients without virological failure (p=0.77). Subtherapeutic NNRTI levels (OR 6.67, 95% CI 1.98-22.43, p<0.002) and poorer adherence (OR 1.54, 95% CI 1.00-2.39, p=0.05) were each associated with higher risk of virologic failure in the matched pair analysis. Unavailability of ART at the treatment centre was the single most common cause (37%) for incomplete adherence in these patients., Conclusions: Virologic failure after one year of first-line ART in rural Cameroon was not associated with transmitted drug resistance, but with reduced drug plasma levels and incomplete adherence. Strategies to assure adherence and uninterrupted drug supply are important factors for therapy success. more...
- Published
- 2014
- Full Text
- View/download PDF
18. Hepatitis E virus infections in HIV-infected patients in Ghana and Cameroon.
- Author
-
Feldt T, Sarfo FS, Zoufaly A, Phillips RO, Burchard G, van Lunzen J, Jochum J, Chadwick D, Awasom C, Claussen L, Drosten C, Drexler JF, and Eis-Hübinger AM
- Subjects
- Adolescent, Adult, Cameroon epidemiology, Child, Child, Preschool, Cohort Studies, Coinfection virology, Cross-Sectional Studies, Enzyme-Linked Immunosorbent Assay, Female, Ghana epidemiology, Hepatitis Antibodies blood, Hepatitis E virus genetics, Hepatitis E virus immunology, Hepatitis E virus isolation & purification, Humans, Immunoglobulin G blood, Immunoglobulin M blood, Infant, Male, Middle Aged, Prevalence, RNA, Viral blood, Retrospective Studies, Reverse Transcriptase Polymerase Chain Reaction, Transaminases blood, Coinfection epidemiology, HIV Infections complications, Hepatitis E epidemiology
- Abstract
Background: Chronic hepatitis E virus (HEV) infections have recently been described in HIV-infected patients. Only few data are available for sub-Saharan Africa, where HIV and HEV are highly co-endemic, and where liver pathology is common in HIV-infected individuals., Objectives: To assess the prevalence of HEV viremia, anti-HEV antibodies, and serum aminotransferase levels in HIV patients in Ghana and Cameroon., Study Design: We retrospectively surveyed a cross-section of patients who were enrolled in cohort studies in Ghana (West Africa), and Cameroon (Central Africa). Plasma samples from 1029 HIV patients from Ghana and 515 patients from Cameroon including 214 children were analyzed for HEV-RNA by two reverse transcription PCR methods. In a subset of 791 patients, anti-HEV IgG and IgM antibodies were analyzed., Results: No HEV-RNA was detected in any of the plasma samples of 1544 patients. HEV seroprevalence was high in adult HIV patients from Ghana (45.3%, n=402) and Cameroon (14.2%, n=289), but low in pediatric HIV patients from Cameroon (2.0%, n=100). Elevations of alanine aminotransferase and aspartate aminotransferase levels were common in adult patients from Ghana (20.8% and 25.4%) and Cameroon (38.9% and 69.8%). The prevalence of hepatitis B virus surface antigen was 11.8% and of hepatitis C virus antibodies 2.5% in our adult Cameroonian study population., Conclusions: Acute or chronic HEV infections did not play a role in liver pathology in two HIV cohorts in Ghana and Cameroon. A better understanding of the epidemiology and genotype-specific characteristics of HEV infections in HIV patients in sub-Saharan Africa is needed., (Copyright © 2013 Elsevier B.V. All rights reserved.) more...
- Published
- 2013
- Full Text
- View/download PDF
19. The α-test: rapid cell-free CD4 enumeration using whole saliva.
- Author
-
Bristow CL, Babayeva MA, Modarresi R, McArthur CP, Kumar S, Awasom C, Ayuk L, Njinda A, Achu P, and Winston R
- Subjects
- CD4-Positive T-Lymphocytes immunology, Female, Humans, Male, Saliva immunology, alpha 1-Antitrypsin immunology, CD4 Lymphocyte Count methods, CD4-Positive T-Lymphocytes cytology, HIV Infections immunology, HIV-1 immunology, Saliva chemistry, alpha 1-Antitrypsin analysis
- Abstract
There is an urgent need for affordable CD4 enumeration to monitor HIV disease. CD4 enumeration is out of reach in resource-limited regions due to the time and temperature restrictions, technical sophistication, and cost of reagents, in particular monoclonal antibodies to measure CD4 on blood cells, the only currently acceptable method. A commonly used cost-saving and time-saving laboratory strategy is to calculate, rather than measure certain blood values. For example, LDL levels are calculated using the measured levels of total cholesterol, HDL, and triglycerides. Thus, identification of cell-free correlates that directly regulate the number of CD4(+) T cells could provide an accurate method for calculating CD4 counts due to the physiological relevance of the correlates. The number of stem cells that enter blood and are destined to become circulating CD4(+) T cells is determined by the chemokine CXCL12 and its receptor CXCR4 due to their influence on locomotion. The process of stem cell locomotion into blood is additionally regulated by cell surface human leukocyte elastase (HLE(CS)) and the HLE(CS)-reactive active α(1)proteinase inhibitor (α(1)PI, α(1)antitrypsin, SerpinA1). In HIV-1 disease, α(1)PI is inactivated due to disease processes. In the early asymptomatic categories of HIV-1 disease, active α(1)PI was found to be below normal in 100% of untreated HIV-1 patients (median=12 μM, and to achieve normal levels during the symptomatic categories. This pattern has been attributed to immune inactivation, not to insufficient synthesis, proteolytic inactivation, or oxygenation. We observed that in HIV-1 subjects with >220 CD4 cells/μl, CD4 counts were correlated with serum levels of active α(1)PI (r(2)=0.93, p<0.0001, n=26) and inactive α(1)PI (r(2)=0.91, p<0.0001, n=26). Administration of α(1)PI to HIV-1 infected and uninfected subjects resulted in dramatic increases in CD4 counts suggesting α(1)PI participates in regulating the number of CD4(+) T cells in blood. With stimulation, whole saliva contains sufficient serous exudate (plasma containing proteinaceous material that passes through blood vessel walls into saliva) to allow measurement of active α(1)PI and the correlation of this measurement is evidence that it is an accurate method for calculating CD4 counts. Briefly, sialogogues such as chewing gum or citric acid stimulate the exudation of serum into whole mouth saliva. After stimulating serum exudation, the activity of serum α(1)PI in saliva is measured by its capacity to inhibit elastase activity. Porcine pancreatic elastase (PPE) is a readily available inexpensive source of elastase. PPE binds to α(1)PI forming a one-to-one complex that prevents PPE from cleaving its specific substrates, one of which is the colorimetric peptide, succinyl-L-Ala-L-Ala-L-Ala-p-nitroanilide (SA(3)NA). Incubating saliva with a saturating concentration of PPE for 10 min at room temperature allows the binding of PPE to all the active α(1)PI in saliva. The resulting inhibition of PPE by active α(1)PI can be measured by adding the PPE substrate SA(3)NA. (Figure 1). Although CD4 counts are measured in terms of blood volume (CD4 cells/μl), the concentration of α(1)PI in saliva is related to the concentration of serum in saliva, not to volume of saliva since volume can vary considerably during the day and person to person. However, virtually all the protein in saliva is due to serum content, and the protein content of saliva is measurable. Thus, active α(1)PI in saliva is calculated as a ratio to saliva protein content and is termed the α(1)PI Index. Results presented herein demonstrate that the α(1)PI Index provides an accurate and precise physiologic method for calculating CD4 counts. more...
- Published
- 2012
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.